Topic: non-Hodgkin lymphoma
Buried within Swiss major Roche's fourth-quarter financials was the announcement that it was dumping a host of early- and late-stage candidates.
Eureka Therapeutics will advance its T-cell treatment for relapsed and refractory CD19+ non-Hodgkin lymphoma into the clinic.
Phase 2 data presented at ASH 2017 suggests that Roche's high expectations for its antibody-drug conjugate for non-Hodgkin lymphoma could be justified.
Juno Therapeutics, which dumped its lead CAR-T program in March, has inked license agreements with Eli Lilly, OncoTracker and Fred Hutch.
Fred Hutchinson scientists have identified biomarkers associated with dangerous side effects possible in cancer patients treated with CAR-T cells.
Scientists at Pfizer have figured out how to make blood cancer cells more vulnerable to attack—by driving them from their favorite hiding place.
Kite Pharma has secured a priority review at the FDA for its CAR-T candidate.
Debiopharm has bought a phase 2 antibody-drug conjugate (ADC) from ImmunoGen to add to its clinical-phase cancer pipeline.
The FDA has granted priority review status to Bayer’s copanlisib, setting the PI3K inhibitor up to speed through the regulatory process in 6 months or less.
Kite Pharma was off by 15% in morning trading after it announced the death of a patient in late April of cerebral edema.